Heart disease risk factors Disease Progression Eradication Over 80s Microbiota Inhibitor Surgery CARCINOGENESIS Rituximab plus chlorambucil IBD Venous thromboembolism IL23 Therapeutics COLON-CANCER Eligibility Dysbiose Résistance Small molecules RISK Monitoring Bactéries Colorectal cancer Colonic epithelial primary cells Gènes Screening Methylation Acceptability Immune cells Neoadjuvant chemotherapy Anti-TNF agents Gene methylation 18 FDG-PET/CT Stricture Intestinal crypts Survival Gene expression Primary sclerosing cholangitis Inflammatory bowel diseases Crohn's disease Dysbiosis Biologics Colon cancer Upper gastrointestinal tract Safety Patient-reported outcome Ulcerative colitis Algorithm Microbiote Cancer Resistance Bacteria Disability DNA METHYLATION Colon Cost effectiveness Disease progression Inflammatory bowel disease Fecal microbiota Clinical guidelines Inflammatory Bowel Diseases Endoscopic treatment Tailored therapy HIV Biomarker Alkylating agents Epigenetics DNA methylation IL12 Colorectal cancer Colibactin and lipids Helicobacter pylori Immunosuppressant Parvimonas micra Clinical trial Genes Rituximab MARKER Cell adhesion Vedolizumab Original Article Clinical Tuberculosis Patients experience Anti-TNF MORTALITY Thérapie ciblée Consensus MALT Drug Inclusion Ustekinumab PCR T1118 translocation MICROBIOTA Crohn’s disease Effectiveness Colectomy Epigénétiques Kidney diseases Méthylation Maintenance therapy Contraindication